Stereotaxis MAGiC cardiac ablation catheter wins FDA approval

Stereotaxis (NYSE:STXS) has won FDA approval for its robotically navigated MAGiC ablation catheter, offering a minimally invasive option for patients who otherwise might not be eligible for cardiac ablation to treat complex and critical heart rhythm disorders.

MAGiC is short for “magnetic interventional ablation catheter,” an abbreviation Stereotaxis also uses for its FDA-cleared MAGiC Sweep robotically navigated high-density electrophysiology (EP) mapping catheter

The St. Louis-based device developer’s MAGiC ablation catheter is designed for radiofrequency cardiac ablation to treat heart arrhythmia.

Specifically, the MAGiC ablation catheter’s indication covers cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and the creation of endocardial lesions to treat supraventricular tachycardia (SVT) in congenital heart disease patients of any age who have underlying anatomic abnormalities and/or a surgical history that limits vascular or target chamber access via conventional manual catheter navigation.

Sign up for Blog Updates